Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

医学 美罗华 内科学 自体干细胞移植 移植 肿瘤科 化疗 干细胞 弥漫性大B细胞淋巴瘤 淋巴瘤 遗传学 生物
作者
Annalisa Chiappella,Maurizio Martelli,Emanuele Angelucci,Ercole Brusamolino,Andrea Evangelista,Angelo Michele Carella,Caterina Stelitano,Giuseppe Rossi,Monica Balzarotti,Francesco Merli,Gianluca Gaïdano,Vincenzo Pavone,Luigi Rigacci,Francesco Zaja,Alfonso Maria D’Arco,Nicola Cascavilla,Eleonora Russo,Alessia Castellino,Manuel Gotti,Angela Giovanna Congiu,Maria Giuseppina Cabras,Alessandra Tucci,Claudio Agostinelli,Giovannino Ciccone,Stefano Pileri,Umberto Vitolo
出处
期刊:Lancet Oncology [Elsevier]
卷期号:18 (8): 1076-1088 被引量:113
标识
DOI:10.1016/s1470-2045(17)30444-8
摘要

The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) is poor. The aim of this study was to investigate the possible benefit of intensification with high-dose chemotherapy and autologous stem-cell transplantation as part of first-line treatment in these patients.We did a multicentre, open-label, randomised, controlled, phase 3 trial with a 2 × 2 factorial design to compare, at two different R-CHOP dose levels, a full course of rituximab-dose-dense chemotherapy (no transplantation group) versus an abbreviated course of rituximab-dose-dense chemotherapy followed by consolidation with R-MAD (rituximab plus high-dose cytarabine plus mitoxantrone plus dexamethasone) and high-dose BEAM chemotherapy (carmustine, etoposide, cytarabine, and melphalan) plus autologous stem-cell transplantation (transplantation group) in young patients (18-65 years) with untreated high-risk diffuse large B-cell lymphoma (aa-IPI score 2-3). At enrolment, patients were stratified according to aa-IPI score and randomly assigned (1:1:1:1) to receive R-CHOP (intravenous rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1·4 mg/m2 on day 1, plus oral prednisone 100 mg on days 1-5) delivered in a 14-day cycle (R-CHOP-14) for eight cycles; high-dose R-CHOP-14 (R-MegaCHOP-14; R-CHOP-14 except for cyclophosphamide 1200 mg/m2 and doxorubicin 70 mg/m2) for six cycles; R-CHOP-14 for four cycles followed by R-MAD (intravenous rituximab 375 mg/m2 on day 1 or 4 plus intravenous cytarabine 2000 mg/m2 and dexamethasone 4 mg/m2 every 12 h on days 1-3 plus intravenous mitoxantrone 8 mg/m2 on days 1-3) plus BEAM (intravenous carmustine 300 mg/m2 on day -7, intravenous cytarabine 200 mg/m2 twice a day on days -6 to -3, intravenous etoposide 100 mg/m2 twice a day on days -6 to -3, plus intravenous melphalan 140 mg/m2 on day -2) and autologous stem-cell transplantation (day 0); or R-MegaCHOP-14 for four cycles followed by R-MAD plus BEAM and autologous stem-cell transplantation. The primary endpoint was failure-free survival at 2 years in the intention-to-treat population. This study is registered with EudraCT (2005-002181-14; 2007-000275-42) and with ClinicalTrials.gov, number NCT00499018.Between Jan 10, 2006, and Sept 8, 2010, 399 patients were randomly assigned to receive transplantation (n=199) or no transplantation (n=200); 203 patients were assigned to receive R-CHOP-14 and 196 were assigned to receive R-MegaCHOP-14. With a median follow-up of 72 months (IQR 57-88), 2-year failure-free survival was 71% (95% CI 64-77) in the transplantation group versus 62% (95% CI 55-68) in the no transplantation group (hazard ratio [HR] 0·65 [95% CI 0·47-0·91]; stratified log-rank test p=0·012). No difference in 5-year overall survival was observed between these groups (78% [95% CI 71-83] versus 77% [71-83]; HR 0·98 [0·65-1·48]; stratified log-rank test p=0·91). Grade 3 or worse haematological adverse events were reported in 183 (92%) of 199 patients in the transplantation group versus 135 (68%) of 200 patients in the no transplantation group. Grade 3 or worse non-haematological adverse events were reported in 90 (45%) versus 31 (16%); the most common grade 3 or worse non-haematological adverse event was gastrointestinal (49 [25%] vs 19 [10%]). Treatment-related deaths occurred in 13 (3%) patients; eight in the transplantation group and five in the no transplantation group.Abbreviated rituximab-dose-dense chemotherapy plus R-MAD plus BEAM and autologous stem-cell transplantation reduced the risk of treatment failure compared with full course rituximab-dose-dense chemotherapy in young patients with diffuse large B-cell lymphoma at high risk. However, these results might not be clinically meaningful, since this improvement did not reflect an improvement in overall survival. These results do not support further consideration of the use of intensification of R-CHOP as an upfront strategy in patients with diffuse large B-cell lymphoma with poor prognosis.Fondazione Italiana Linfomi.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
耿耿完成签到,获得积分10
1秒前
3秒前
3秒前
4秒前
回忆告白完成签到,获得积分10
4秒前
吃猫的鱼发布了新的文献求助10
5秒前
尽快毕业完成签到 ,获得积分10
5秒前
行歌发布了新的文献求助10
5秒前
高大黄蜂发布了新的文献求助10
7秒前
7秒前
7秒前
9秒前
9秒前
小雅完成签到,获得积分10
9秒前
10秒前
wang5945发布了新的文献求助10
11秒前
11秒前
大黄完成签到,获得积分10
12秒前
tion66完成签到 ,获得积分10
13秒前
13秒前
白菜发布了新的文献求助10
13秒前
大模型应助syl采纳,获得10
14秒前
Joey发布了新的文献求助10
14秒前
uniphoton发布了新的文献求助10
14秒前
15秒前
15秒前
香蕉觅云应助科研通管家采纳,获得10
15秒前
我是老大应助科研通管家采纳,获得10
15秒前
斯文败类应助科研通管家采纳,获得10
15秒前
FashionBoy应助科研通管家采纳,获得10
16秒前
16秒前
大壮应助科研通管家采纳,获得10
16秒前
16秒前
LaoLuo发布了新的文献求助100
18秒前
慕容飞凤完成签到,获得积分10
18秒前
20秒前
21秒前
21秒前
21秒前
ks发布了新的文献求助20
21秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Handbook of Prejudice, Stereotyping, and Discrimination (3rd Ed. 2024) 1200
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 1000
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3244375
求助须知:如何正确求助?哪些是违规求助? 2888048
关于积分的说明 8251163
捐赠科研通 2556525
什么是DOI,文献DOI怎么找? 1384950
科研通“疑难数据库(出版商)”最低求助积分说明 649943
邀请新用户注册赠送积分活动 626045